Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders (OPAL)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00326144
First received: May 15, 2006
Last updated: March 24, 2009
Last verified: March 2009
  Purpose

The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the treatment of Major Depressive Disorders PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


Condition Intervention Phase
Major Depressive Disorder
Drug: Quetiapine fumarate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Mono-Therapy in the Treatment of Adult Patients With Major Depressive Disorder

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate the efficacy of Quetiapine SR compared with placebo in the treatment of patients with MDD as assessed by change from randomization to Week 8 in the MADRS total score

Secondary Outcome Measures:
  • To evaluate if Quetiapine SR improves the health-related quality of life of patients with MDD, compared to placebo
  • To evaluate if quetiapine SR reduces anxiety symptoms in patients with MDD, compared to placebo

Enrollment: 310
Study Start Date: April 2006
Study Completion Date: May 2007
Intervention Details:
    Drug: Quetiapine fumarate
    Other Name: Seroquel
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is able to provide written informed consent before beginning any study related procedures
  • Patient has a documented clinical diagnosis of major depressive disorder
  • Patient is able to understand and comply with the requirements of the study, as judged by a study investigator

Exclusion Criteria:

  • Patients with a history of non-compliance as judged by the study investigator
  • Patients with a known lack of response to previous treatment with quetiapine
  • Patients who have participated in a clinical trial within 4 weeks of randomization
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00326144

  Hide Study Locations
Locations
United States, Arizona
Research Site
Phoenix, Arizona, United States
United States, Arkansas
Research Site
Little Rock, Arkansas, United States
United States, California
Research Site
Anaheim, California, United States
Research Site
El Centro, California, United States
Research Site
Garden Grove, California, United States
Research Site
National City, California, United States
Research Site
Riverside, California, United States
United States, Connecticut
Research Site
Hartford, Connecticut, United States
United States, Delaware
Research Site
Wilmington, Delaware, United States
United States, Florida
Research Site
Altamonte Springs, Florida, United States
Research Site
DeLand, Florida, United States
Research Site
Maitland, Florida, United States
Research Site
New Port Richey, Florida, United States
United States, Georgia
Research Site
Atlanta, Georgia, United States
Research Site
Decatur, Georgia, United States
Research Site
Roswell, Georgia, United States
United States, Illinois
Research Site
Naperville, Illinois, United States
United States, Indiana
Research Site
Indianapolis, Indiana, United States
Research Site
Lafayette, Indiana, United States
United States, Kentucky
Research Site
Owensboro, Kentucky, United States
United States, Louisiana
Research Site
New Orleans, Louisiana, United States
United States, Massachusetts
Research Site
Braintree, Massachusetts, United States
Research Site
Cambridge, Massachusetts, United States
Research Site
Pittsfield, Massachusetts, United States
United States, Minnesota
Research Site
Minneapolis, Minnesota, United States
United States, Missouri
Research Site
St. Louis, Missouri, United States
United States, New York
Research SIte
Staten Island, New York, United States
United States, Ohio
Research Site
Avon Lake, Ohio, United States
Research Site
Cincinnati, Ohio, United States
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Research Site
Allentown, Pennsylvania, United States
United States, Tennessee
Research Site
Memphis, Tennessee, United States
United States, Texas
Research Site
DeSoto, Texas, United States
Research Site
Houston, Texas, United States
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Seroquel Medical Science Director, MD AstraZeneca
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00326144     History of Changes
Other Study ID Numbers: D1448C00003, OPAL
Study First Received: May 15, 2006
Last Updated: March 24, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
MDD
Depression

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Quetiapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on April 17, 2014